Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

Beijing Wantai Biological Phar / Index Rebalance

Beijing Wantai Biological Phar (603392 CH)

<ul>
<li>CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.</li>
<li>We expect five ADDs/DELs for the CSI Medical Service index during the upcoming index rebal  event based on the latest available data.</li>
<li>Nearly 95% of the reference period is now complete. We currently estimate one-way flow to be US$301mn.</li>
</ul>


CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.
We expect five ADDs/DELs for the CSI Medical Service index during the upcoming index rebal  event based on the latest available data.
Nearly 95% of the reference period is now complete. We currently estimate one-way flow to be US$301mn.


Quiddity Leaderboard CSI Medical Dec26: Expectations Have Changed; US$301mn One-Way

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Cofoe Medical Technology  Lt / Equity Capital Markets

<ul>
<li>Cofoe’s heavy reliance on marketing-driven growth models, continuous shrinking R&amp;D investment, impairment of goodwill, and related-party transactions remain the core issues for investors, thus leading to worrying long-term growth prospects.</li>
<li>Cofoe’s overseas revenue increased by 405% YoY, but this was mainly due to the consolidation effect brought about by the acquisitions of Shanghai Huazhou and Humana, rather than organic growth.</li>
<li>Considering the cautious attitude of HK investors towards "heavy marketing, light R&amp;D" model, we think reasonable P/E range could be 18-25x. Based on 2026 forecast, market value is RMB8.28-11.5 billion.  </li>
</ul>


Cofoe’s heavy reliance on marketing-driven growth models, continuous shrinking R&amp;D investment, impairment of goodwill, and related-party transactions remain the core issues for investors, thus leading to worrying long-term growth prospects.
Cofoe’s overseas revenue increased by 405% YoY, but this was mainly due to the consolidation effect brought about by the acquisitions of Shanghai Huazhou and Humana, rather than organic growth.
Considering the cautious attitude of HK investors towards "heavy marketing, light R&amp;D" model, we think reasonable P/E range could be 18-25x. Based on 2026 forecast, market value is RMB8.28-11.5 billion.  


Pre-IPO Cofoe Medical Technology (PHIP Updates) - Some Points Worth the Attention

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 200 stocks over the last week. The average A-H premium was 92.3% as of Oct 9th.</li>
<li>The average A-H premium changed by 3.7ppt week-on-week, led by materials, industrials, utilities.</li>
<li>We highlight weekly changes in A-H premium for Innocare, Ganfenglithium, China East Air, Yofc.</li>
</ul>


We analyse the changes of A-H premium on 200 stocks over the last week. The average A-H premium was 92.3% as of Oct 9th.
The average A-H premium changed by 3.7ppt week-on-week, led by materials, industrials, utilities.
We highlight weekly changes in A-H premium for Innocare, Ganfenglithium, China East Air, Yofc.


A-H Premium Weekly (Oct 9th): Innocare, Ganfenglithium, China East Air, Yofc

<ul>
<li>We analyse the changes of A-H premium on 195 stocks over the last week. The average A-H premium was 85.5% as of Sep 25th.</li>
<li>The average A-H premium changed by 0.5ppt week-on-week, led by communication services, real estate, materials and offset by industrials.</li>
<li>We highlight weekly changes in A-H premium for Innocare Pharma, Vgt, ABC, Yofc.</li>
</ul>


We analyse the changes of A-H premium on 195 stocks over the last week. The average A-H premium was 85.5% as of Sep 25th.
The average A-H premium changed by 0.5ppt week-on-week, led by communication services, real estate, materials and offset by industrials.
We highlight weekly changes in A-H premium for Innocare Pharma, Vgt, ABC, Yofc.


A-H Premium Weekly (Sep 25th): Innocare Pharma, Vgt, ABC, Yofc

<ul>
<li>We analyse the changes of A-H premium on 195 stocks over the last week. The average A-H premium was 85.1% as of Sep 18th.</li>
<li>The average A-H premium changed by 1.6ppt week-on-week, led by consumer staples, communication services, information technology and offset by consumer discretionary, utilities, energy.</li>
<li>We highlight weekly changes in A-H premium for Minsheng Bank, Air China, Ceb Bank, China East Air.</li>
</ul>


We analyse the changes of A-H premium on 195 stocks over the last week. The average A-H premium was 85.1% as of Sep 18th.
The average A-H premium changed by 1.6ppt week-on-week, led by consumer staples, communication services, information technology and offset by consumer discretionary, utilities, energy.
We highlight weekly changes in A-H premium for Minsheng Bank, Air China, Ceb Bank, China East Air.


A-H Premium Weekly (Sep 18th): Minsheng Bank, Air China, Ceb Bank, China East Air

China

Cofoe Medical Technology Co.,Ltd. manufactures and distributes medical equipment. The Company produces health monitoring equipment, rehabilitation aid equipment, medical care equipment, medicine physiotherapy equipment, respiratory support equipment, and others. Cofoe Medical Technology also produces daily necessities, electronics, hygiene products, cosmetics, and other products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cofoe Medical Technology Lt (301087 CH)

Quiddity Leaderboard CSI Medical Dec26: Expectations Have Changed; US$301mn One-Way

There are three index members failing the liquidity test by narrow margins and they should be monitored until the end of the reference period.

Janaghan Jeyakumar, CFA

Pre-IPO Cofoe Medical Technology (PHIP Updates) - Some Points Worth the Attention

Investors concerned about Cofoe's outlook due to heavy marketing/light R&D model. Overseas business remain uncertain. Reasonable P/E estimated at...

Xinyao (Criss) Wang

A-H Premium Weekly (Oct 9th): Innocare, Ganfenglithium, China East Air, Yofc

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Innocare, Ganfenglithium, China East Air, Yofc.

Ke Yan, CFA, FRM

A-H Premium Weekly (Sep 25th): Innocare Pharma, Vgt, ABC, Yofc

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Innocare Pharma, Victory Giant Technology, ABC, Yofc.

Ke Yan, CFA, FRM

A-H Premium Weekly (Sep 18th): Minsheng Bank, Air China, Ceb Bank, China East Air

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Minsheng Bank, Air China, Ceb Bank, China East Air.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Quiddity Leaderboard CSI Medical Dec26: Expectations Have Changed; US$301mn One-Way

There are three index members failing the liquidity test by narrow margins and they should be monitored until the end of the reference period.

Janaghan Jeyakumar, CFA

Pre-IPO Cofoe Medical Technology (PHIP Updates) - Some Points Worth the Attention

​Investors concerned about Cofoe's outlook due to heavy marketing/light R&D model. Overseas business remain uncertain. Reasonable P/E estimated at...

Xinyao (Criss) Wang

A-H Premium Weekly (Oct 9th): Innocare, Ganfenglithium, China East Air, Yofc

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Innocare, Ganfenglithium, China East Air, Yofc.

Ke Yan, CFA, FRM

A-H Premium Weekly (Sep 25th): Innocare Pharma, Vgt, ABC, Yofc

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Innocare Pharma, Victory Giant Technology, ABC, Yofc.

Ke Yan, CFA, FRM

A-H Premium Weekly (Sep 18th): Minsheng Bank, Air China, Ceb Bank, China East Air

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Minsheng Bank, Air China, Ceb Bank, China East Air.

Ke Yan, CFA, FRM

Investors concerned about Cofoe's outlook due to heavy marketing/light R&D model. Overseas business remain uncertain. Reasonable P/E estimated at...